Business Trends– category –
-
Cellistic Unveils Specialized CDMO Services for iPSC-Derived Cell Therapies, Expediting Development from Early Stages to GMP
Cellistic Belgium Overview Cellistic is offering specialized Contract Development and Manufacturing Organization (CDMO) services tailored for iPSC-derived cell therapies. Leveraging bioreactor-based, GMP-compliant processes, the company ... -
Scribe Therapeutics Files for Nasdaq IPO, Advancing CRISPR-Based Cardiovascular Disease Platform STX-1150 for Hypercholesterolemia
Endpoints News USA Overview Scribe Therapeutics, co-founded by Nobel laureate Dr. Jennifer Doudna, has filed for an initial public offering (IPO) on Nasdaq. This move signals a crucial strategy for the company to expand its CRISPR-based ... -
MeiraGTx Secures Up To $400 Million From Oberland Capital to Support Commercialization of Two Gene Therapies
Fierce Biotech USA Overview MeiraGTx has finalized a funding agreement with Oberland Capital totaling up to $400 million. This capital will support the commercialization of the company's two late-stage gene therapy candidates: bota-vec f... -
Fate Therapeutics Receives FDA IND Approval for CAR-T Therapy FT839 for Autoimmune Diseases, Advancing to Phase 1/2 Clinical Trial
GlobeNewswire USA Overview Fate Therapeutics has received U.S. FDA Investigational New Drug (IND) approval for its CAR-T cell therapy candidate, FT839, targeting autoimmune diseases. The company plans to initiate a Phase 1/2 basket clini... -
RoosterBio and Applied StemCell Announce Strategic Partnership for iPSC-Based Bioprocess Solutions
BioSpace USA Overview RoosterBio and Applied StemCell have announced a strategic partnership aimed at developing and commercializing iPSC-based bioprocess solutions. This collaboration combines Applied StemCell's GMP-compatible iPSC tech... -
RoslinCT and BlueRock Therapeutics Partner to Expand Supply of Clinical-Grade iPSC Lines, Supporting Cell Therapy Development
PharmaSource UK Overview RoslinCT has announced a strategic partnership with BlueRock Therapeutics to expand access to clinical-grade iPSC lines for cell therapy developers. This collaboration integrates BlueRock's high-quality clinical-... -
Siren Biotechnology Secures $8 Million Non-Dilutive Funding from CIRM to Advance Brain Tumor Gene Therapy SRN-101
Phacilitate USA Overview Siren Biotechnology has been awarded $8 million in non-dilutive funding from the California Institute for Regenerative Medicine (CIRM). This significant capital injection will be used to support the clinical deve... -
FDA Approves Casgevy for Expanded Use in Pediatric Patients Aged 2 and Older with Sickle Cell Disease and Transfusion-Dependent Beta-Thalassemia
Seeking Alpha USA Overview Crispr Therapeutics and Vertex Pharmaceuticals announced that the U.S. FDA has approved an expanded indication for Casgevy (exagamglogene autotemcel) to include pediatric patients aged 2 and older with sickle c... -
Catalent and Nanoscope Expand Supply Partnership for Commercialization of Optogenetic Gene Therapy MCO-010 for Retinal Degenerative Diseases
LucidQuest Ventures USA Overview Catalent and Nanoscope Therapeutics have expanded their partnership to support the late-stage development and commercial supply of MCO-010, an optogenetic gene therapy candidate for retinal degenerative d... -
STEMCELL Technologies and CCRM Partner to Accelerate Cell Therapy Development by Expanding Access to Matched GMP/RUO iPSC Lines
Business Wire USA Overview STEMCELL Technologies and the Centre for Commercialization of Regenerative Medicine (CCRM) have announced a strategic partnership to expand access to high-quality human iPSC starting materials. This collaborati...
